Kangfang Biotech's partner Summit announces the results of the global Phase III study on Yvexi monoclonal antibody, and plans to submit a marketing application in the US.

On May 30th, Summit, a listed company on the US stock market, announced the topline results of the global Phase III clinical trial HARMONi for the drug Ivosidenib. The results showed that, compared to chemotherapy alone, the combination of Ivosidenib and chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival as the primary endpoint in patients with EGFR-mutated non-small cell lung cancer who had disease progression after EGFR TKI treatment, with a hazard ratio of 0.52 (95% CI: 0.41-0.66; p <0.0001).